Iomai awarded key vaccine technology patent.Iomai Corporation (Gaithersburg, MD) announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has awarded a new United States Patent 7,037,499 "Adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant)
1. assisting or aiding.
2. a substance that aids another, such as an auxiliary remedy.
3. for transcutaneous transcutaneous /trans·cu·ta·ne·ous/ (-ku-ta´ne-us) transdermal.
Transdermal. immunization immunization: see immunity; vaccination. ". The patent outlines methods for inducing an immune response to Iomai's novel skin-patch-based vaccines.
The patent's claims expand the coverage for the company's proprietary transcutaneous immunization (TCI (Trustworthy Computing Initiative) An umbrella term from Microsoft for its efforts to improve security in Windows. TCI was announced in 2002 after viruses such as Code Red and Nimda had succeeded in attacking numerous Windows computers. ) technology, a unique method of vaccine delivery with benefits including needle-free administration and the ability to deliver types of vaccines that are not viable by an intramuscular intramuscular /in·tra·mus·cu·lar/ (-mus´ku-ler) within the muscular substance.
adj. Abbr. IM
Within a muscle. (IM) route. Iomai's TCI technology uses a patch applied to the skin like a bandage and worn for several hours to deliver vaccine and/or adjuvants to a group of antigen-presenting cells (called Langerhans cells) in the skin called that carry the vaccine to the nearby lymph nodes where they prompt a sustained immune response.
The TCI technology was initially developed by Iomai founder and chief scientific officer Dr. Gregory Glenn, M.D. when he made the observation while a researcher at the Walter Reed Army Institute of Research This article is about the U.S. Army medical research institute (not the hospital). Otherwise, see Walter Reed (disambiguation).
The Walter Reed Army Institute of Research (WRAIR) is the largest biomedical research facility administered by the U.S. that the skin is a highly attractive immune environment for vaccination. The Walter Reed Army Institute of Research has granted Iomai an exclusive worldwide license to the TCI technology.
"This patent confirms our position as the first company to design a patch-based system that administers vaccine to the skin -- a major competitive advantage," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "This allows us to continue our efforts to develop the first-ever vaccine for traveler's diarrhea in the United States and a needle-free influenza vaccine patch that would be simpler to administer than injectable vaccines."
The patent was awarded to the United States government and lists Dr. Glenn as a co-inventor. With the new patent, Iomai now holds the exclusive license to four United States patents and 20 foreign patents, and has filed more than a dozen non-provisional patent applications in the United States and more than 30 foreign applications.
Iomai discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic pandemic /pan·dem·ic/ (pan-dem´ik)
1. a widespread epidemic of a disease.
2. widely epidemic.
Epidemic over a wide geographic area.
n. flu and one to prevent E. coli-related travelers' diarrhea.